News & Updates

Asha Therapeutics is now First Atom Therapeutics

ATLANTA, GA, UNITED STATES, May 20, 2025 /EINPresswire.com/ -- CMT Research Foundation has invested in a research project with Asha...

NEW YORK, April 23, 2025 /PRNewswire/ -- Advancium Health Network, a public charity dedicated to advancing therapies for rare diseases,...

November 13, 2024 09:30 AM Eastern Standard Time CINCINNATI--( BUSINESS WIRE )-- Asha Therapeutics  (Asha), a life sciences company...

CINCINNATI--(BUSINESS WIRE)--Asha Therapeutics (Asha) (www.ashatherapeutics.com), a life sciences company designing de novo disease...

CINCINNATI--(BUSINESS WIRE)--Asha Therapeutics (Asha), (www.ashatherapeutics.com), a life sciences company, is leveraging its...

Asha Therapeutics (Asha), (www.ashatherapeutics.com), a biopharmaceutical company revolutionizing the traditional multi-year drug...

August 31, 2023 - Earlier this week, innovation took center stage at the BLUE KNIGHT™ QuickPitch: Activating for the Future. 10...

Asha Therapeutics will be presenting new data at the 6th Annual Next-Gen Immuno-oncology Conference showing robust efficacy of their Beta-Catenin targeted protein degrader (TPD) ASHA-044 in a CDX model of colorectal carcinoma (CRC). CRC is one of the most aggressive and metastatic tumors with incidence of disease skyrocketing over the past 5 years, particular in young ~40yr old populations. CRC tumors are typically characterized by the lack of appreciable immune cell infiltra

Asha Therapeutics presented exciting new data for their lead Parkinson's Disease therapeutic ASHA-091 in one of its secondary indications...

See Full Press Release Here Asha Therapeutics presented their novel VHL recruiter technology at Third Annual Ligase Targeting Drug...

Asha Therapeutics' scientific co-founder and CSO, Dr. Bradlee Heckmann will be presenting at the international AD/PD 2023 meeting in...

February 10, 2023 Asha Therapeutics is pleased to announce the appointment of Dr. Craig Blackstone as a member of its Board of...

Asha Therapeutics (Asha), announced today the appointment of Kirsten Flowers to its Board of Directors. Asha’s PRISM™ technology has resulted in a pipeline of assets that treats neurological disease by considering neuronal deterioration and loss from multiple vantage points. Within Asha’s pipeline, lead asset ASHA-091 is a first-in-class, near clinic-ready custom-designed brain penetrant compound that restores the mitochondrial network, promoting cell survival over cell death

Asha Therapeutics www.ashatherapeutics.com announced today that it has appointed Dr. Craig Blackstone, Chief of the Movement Disorders...

Sam Shrivastava (Asha CEO) and Dr. Bradlee Heckmann (Asha CSO) present updates on neuro-oncology assets and ASHA-044

Asha Therapeutics' lead mitochondrial dynamics targeting drug ASHA-091 demonstrates robust efficacy and safety in preclinical murine...